Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Caraco effect visible - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Nov 4, 2004

    Sun Pharma: Caraco effect visible

    Performance Summary
    Sun Pharmaceutical declared its 2QFY05 results recently. The topline of the company grew by 10% while the growth in bottomline was 29% on a YoY basis. The improvement in bottomline was mainly due to a huge 490 basis points improvement in its operating profit margin in 2QFY05, on the back of savings made in raw material costs and other expenditure.

    (Rs m) 2QFY04 2QFY04 % Change 2QFY04 2QFY04 % Change
    Net sales 2,833 3,122 10.2% 5,273 6315 19.8%
    Total Expenditure 1,915 1,955 2.1% 3,524 4,129 17.2%
    Opearting profit 919 1,167 27.0% 1,749 2,185.2 24.9%
    Operating Profit margin(%) 32.4% 37.4%   33.2% 34.6%  
    Other Income 48 24 -49.0% 91 68 -25.4%
    Interest 18 5 -73.9% 38 11 -71.1%
    Depreciation 63 86 38.1% 127 166 30.8%
    Profit before tax 887 1,101 24.1% 1,674 2,076 24.0%
    Tax 57 31 -46.8% 104 68 -34.3%
    Profit after tax 829 1,070 29.0% 1,571 2,007.5 27.8%
    Profit after tax margin (%) 29.3% 34.3%   29.8% 31.8%  
    Minority interest 127 39 -69.6% 231 92 -60.1%
    Net profit 702 1031 46.9% 1,339 1,915 43.0%
    No. of shares 186 186   186 186  
    Earning per share* 15 22   14 21  
    P/E ratio         22.4  

    Company's background
    Sun Pharma is a leading domestic pharma company with a strong presence in the lifestyle therapeutic segment. However, it started focusing in the exports market and in FY02 it acquired Caraco Pharma in the US. Further, it increased its stake in Caraco pharma in FY04 to 61% taking over majority control. With the help of its US subsidiary, the company has been able to grow its US business, which brings in synergies with Sun's business by backward integration in both manufacturing and R&D.

    What has driven performance in 2QFY05?
    Sales: Sun Pharma’s topline growth was fuelled by a strong performance in its formulations business, which recorded a 15% growth during 2QFY05. In the first half of FY05 the sales growth was 21% in formulations exports, which basically grew due to strong growth shown by Sun pharma's US based subsidiary Caraco Pharma. Caraco Pharma has shown a growth of 50% in the topline in the September quarter. However, revenues from the bulk drugs segment have slipped marginally due to the company's focus on formulations business. Sun Pharma’s core therapeutic segments of psychiatry, neurology, cardiology, diabetology, and gastroenterology, which make up for 70% of the domestic formulations sales, grew by about 12% as a whole during the quarter.

    Sales Break-up
    (Rs m) 2QFY04 2QFY05 %Change 1HFY03 1HFY04 %Change
    Formulations 1,563 1,725 10.4% 2,854 3,504 22.8%
    Bulk 297 290 -2.4% 554 551 -0.5%
    Others - 19 - - 30 -
    Total (A) 1,860 2,034 9.3% 3,408 4,085 19.9%
    Formulations 743 862 16.0% 1,392 1,687 21.2%
    Bulk 230 226 -1.5% 473 543 14.9%
    Total (B) 973 1,088 11.8% 1,865 2,230 19.6%
    Grand Total ((A)+(B)) 2,833 3,122 10.2% 5,273 6,315 19.8%

    Operating margin: The operating margin of the company expanded by 490 basis points basically due to increased contribution from the exports business. With the company transferring Caraco pharma's manufacturing activities to the Indian plants, the company has been able to expand margins further. Despite a huge surge in R&D expenditure (8.2% of sales in 2QFY05), company managed to increase its operating profit due the savings in raw material costs and other expenditures.

    Net Profit: The profit after tax has risen by 29% and the net profit margin expanded by 500 basis points. The major contribution to this expansion comes from improvement in its operating performance, however, lower tax charges due to increasing contribution from exports has also helped the cause.

    What to expect?
    At 462 the stock is trading at a P/E ratio of 22.4 times its annaulised 1HFY05 earnings. With its US subsidiary now turning profitable, the company is in a position to leverage its cost advantage in manufacturing and R&D by launching new drugs through Caraco Pharma in the US markets. Also, being a dominant player in the lifestyle segment in the domestic market, the company might see a good growth rate going forward as these segment are amongst the fastest growing therapeutic segments in the domestic market.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Caraco effect visible ". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 (Close)


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts